AbbVie, Gilead, Janssen dazzle with Hep C data
This article was originally published in Scrip
Executive Summary
A clutch of presentations at the International Liver Conference of the European Association for the Study of the Liver (EASL) over the weekend served to underline the impressive arsenal of new weapons that the pharma industry is preparing to unleash against hepatitis C.